💨 Abstract

The World Health Organization (WHO) now recommends including lenacapavir for HIV prevention. Approved recently, this semestral injection has shown to drastically reduce HIV infection risk. The WHO's guidelines also support the use of rapid diagnostic tests for HIV. Lenacapavir’s semestral schedule aims to improve adherence. However, there are concerns about funding cuts to global HIV prevention efforts, which may lead to increased HIV-related deaths if not addressed.

Courtesy: WTOP Staff